Fracture risk tool useful in women with breast cancer initiating aromatase inhibitor therapy

The FRAX tool takes into account certain factors to determine the risk of bone fracture in the general population. In a Journal of Bone and Mineral Research study, the tool was effective at determining fracture risk for women with breast cancer who were treated with aromatase inhibitors, which cause accelerated bone loss, when combined with bone mineral density measurements.

However, the results also question the practice of considering a "secondary cause of osteoporosis" when the FRAX tool is used without bone mineral density, because this can lead to overestimation of fracture risk. Nonetheless, it is very important to determine fracture risk in women receiving aromatase inhibitor therapy who will most likely experience during treatment.

"We hope that our data will help to inform clinical guidelines regarding fracture risk assessment in women with , and the incorporation of FRAX in management algorithms of those receiving aromatase inhibitors," said lead author Dr. William D. Leslie, of the University of Manitoba, in Canada.


Explore further

Past falls can help predict an individual's risk of bone fracture independent of other factors

More information: Journal of Bone and Mineral Research (2019). DOI: 10.1002/jbmr.3726
Provided by Wiley
Citation: Fracture risk tool useful in women with breast cancer initiating aromatase inhibitor therapy (2019, May 9) retrieved 16 July 2019 from https://medicalxpress.com/news/2019-05-fracture-tool-women-breast-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more